Treatment-Resistant Depression: When Standard Treatments Have Not Worked

For most people who seek treatment for depression, a combination of psychotherapy and antidepressant medication produces meaningful improvement. First-line antidepressants such as SSRIs and SNRIs are effective, well-tolerated, and have helped tens of millions of people reclaim their lives from depression. But for a significant minority, these standard approaches simply do not work well enough. If you are in that group, this blog is written for you.

Treatment-resistant depression (TRD) is a real, recognized clinical condition. It is not a reflection of insufficient willpower, inadequate effort, or a character flaw. It reflects the biological complexity of depression and the current limits of our ability to predict which treatment will work for any given person. Understanding TRD, what defines it, why it happens, and what options exist, is an important step toward finding a path that works.

Defining Treatment-Resistant Depression

TRD is typically defined as depression that has not responded adequately to at least two different antidepressant medications, given at appropriate doses for sufficient duration, generally eight to twelve weeks each. By this definition, approximately 30 to 35 percent of people with major depressive disorder meet the threshold for TRD at some point during their illness. Applied to the 21.4 million Americans who experienced a major depressive episode in 2024, this represents millions of people living with inadequately treated depression despite seeking care and trying medication.

Partial response, where symptoms improve but do not resolve, is also common and clinically significant. Living with residual depressive symptoms even after treatment affects functioning, quality of life, and risk of future depressive episodes. The goal of care is not merely partial improvement; it is genuine, sustained wellbeing.

Why Does Standard Treatment Fail for Some People?

The short answer is that we do not yet have reliable ways to predict which antidepressant will work for any individual patient. Depression is not a single disease. It is a clinical syndrome, a cluster of symptoms that can arise from different underlying biological mechanisms. Some depressions may be primarily driven by serotonergic dysregulation, for which SSRIs are well-suited. Others may have a more prominent inflammatory component, or involve the glutamate system more centrally, or reflect neuroendocrine disruption. Currently, the standard clinical approach is largely trial and error: prescribe, wait, assess response, adjust.

Genetic factors also play a role. Pharmacogenomic testing, which analyzes how an individual’s genes affect drug metabolism, has become increasingly available and can help identify medications more likely to be effective or poorly tolerated. Other factors including medical comorbidities, sleep disorders, substance use, trauma history, and chronic stress can all affect antidepressant response and may need to be addressed as part of a comprehensive treatment approach.

The Human Cost of Undertreated Depression

TRD is associated with substantially higher rates of functional impairment, absenteeism, hospitalization, and healthcare utilization compared to depression that responds to initial treatment. People living with TRD often describe years of trying medication after medication, each with its own side effect profile and adjustment period, without finding adequate relief. The cumulative toll of sustained depression on relationships, career, physical health, and quality of life is profound.

Suicidal ideation is more prevalent among people with TRD than among those whose depression responds to standard treatment. This makes identifying effective treatments for TRD not merely a quality-of-life issue but a life-or-death clinical priority. The emergence of ketamine as a rapid-acting intervention for both depressive symptoms and suicidal ideation has therefore been particularly significant.

Novel and Emerging Treatments for TRD

Ketamine and Esketamine

Ketamine’s mechanism of action, targeting the glutamate system through NMDA receptor antagonism rather than monoamine systems, makes it biologically distinct from all prior antidepressants. This different mechanism explains why it can work for patients who have not responded to SSRIs, SNRIs, MAOIs, or tricyclics. Multiple randomized controlled trials have demonstrated significant antidepressant effects in TRD populations, often within hours to days of treatment. In January 2025, the FDA expanded the approval for esketamine (Spravato) to include its use as a standalone treatment for TRD, an important regulatory acknowledgment of the accumulated evidence.

Response rates in TRD trials have been meaningful. A landmark clinical study found that 22.5 percent of patients receiving esketamine achieved remission at four weeks compared to 7.6 percent receiving placebo, a clinically significant difference in a population that had previously failed multiple treatments. Ketamine is not a guarantee of response, but for many people with TRD it represents a genuinely new option with a different probability of success than continuing to cycle through treatments in the same pharmacological class.

Transcranial Magnetic Stimulation (TMS)

TMS is a non-invasive brain stimulation technique that uses magnetic fields to stimulate nerve cells in regions of the brain associated with mood regulation. It is FDA-cleared for TRD and does not require anesthesia or involve systemic medication. Response rates in TRD range from 50 to 60 percent, with remission rates around 30 percent across major clinical trials. TMS requires multiple sessions across several weeks, which can be a logistical consideration for some patients.

Electroconvulsive Therapy (ECT)

ECT remains one of the most effective treatments available for severe TRD, with response rates of 60 to 80 percent in carefully selected patients. Modern ECT is performed under general anesthesia and is substantially different from older historical approaches. It is typically considered for patients with severe TRD, particularly those with psychotic features, catatonia, or in life-threatening situations. Memory effects and the need for hospitalization or intensive outpatient scheduling are relevant clinical considerations.

Medication Augmentation Strategies

Even within the pharmacological approach, TRD does not necessarily mean no options remain. Augmentation strategies, adding a second medication to an antidepressant that has produced partial response, are an important part of the TRD treatment toolkit. Lithium augmentation, atypical antipsychotic augmentation, thyroid hormone, and other approaches have evidence for enhancing antidepressant response. A thorough clinical evaluation can identify whether augmentation strategies have been fully explored.

The Importance of Comprehensive Evaluation

Not all treatment resistance is the same. For some people, what appears to be TRD may reflect undertreated comorbidities, medication doses that were never optimized, insufficient trial duration, or unaddressed contributing factors like sleep apnea, thyroid dysfunction, or alcohol use. A comprehensive evaluation by a psychiatrist or psychiatric provider familiar with TRD should include a careful review of prior treatment history, medical and psychiatric comorbidities, current medication regimen, and lifestyle factors.

At Vantage Telehealth, our providers approach TRD with the seriousness and thoroughness it deserves. If you have been living with depression that has not responded to prior treatment, we encourage you to begin a clinical conversation about your history and your options. You deserve care that goes beyond repeating the same approaches and actually addresses where you are and what you specifically need. That conversation starts with a brief intake, and we are here when you are ready.

Learn more about ketamine-assisted therapy at Vantage

Frequently Asked Questions

What is treatment-resistant depression?

Treatment-resistant depression, or TRD, is generally defined as major depressive disorder that has not adequately responded to at least two different antidepressant medications, each taken at an adequate dose for an adequate duration. It affects roughly one-third of people with depression. TRD is a clinical diagnosis, not a personal failure.

What are the newest treatments for TRD?

Newer options include intranasal esketamine (Spravato), which is FDA-approved for TRD, as well as ketamine-assisted therapy and transcranial magnetic stimulation (TMS). Emerging research is also exploring psilocybin-assisted therapy under regulated protocols. All of these require careful clinical evaluation.

How is TRD diagnosed?

TRD is diagnosed by a licensed clinician who reviews your medication history, the doses and durations you tried, and your treatment response. A structured interview and standardized depression rating scales are commonly used. There is no single lab test — clinical judgment is central.

Can ketamine therapy help with treatment-resistant depression?

Yes — ketamine and esketamine both have clinical evidence for rapidly reducing depressive symptoms in TRD, often within hours or days. Ketamine is not a cure and is generally used alongside integration therapy and ongoing mental health care. Providers in our partner medical network evaluate whether it is appropriate on a case-by-case basis.

Is TRD more common than people think?

Yes — an estimated one in three adults with major depressive disorder does not respond adequately to first-line antidepressants. Many go years without knowing effective alternatives exist. Better screening and expanded access to treatments like ketamine are changing that picture.

What should someone do if antidepressants have not worked?

The most important step is a re-evaluation with a licensed clinician who can review what has been tried, at what doses, and for how long. Options may include switching medications, augmentation strategies, therapy adjustments, or treatments like ketamine or TMS. You are not out of options — a fresh clinical review is usually the right first step.

See how Vantage Telehealth can help — Get Started →

Disclaimer: This content is for informational and educational purposes only and is not intended as medical advice, diagnosis, or treatment recommendation. Ketamine is a Schedule III controlled substance and its use for mental health conditions must be supervised by a qualified medical provider. Clinical appropriateness for ketamine therapy is determined on an individual basis by your provider. If you are experiencing a mental health crisis or thoughts of suicide, please call or text 988 (Suicide and Crisis Lifeline), call 911, or go to your nearest emergency room. The information presented here reflects general educational content and may not apply to your specific situation. Always consult a licensed healthcare professional before starting any new treatment.